Recombinant FVIII concentrate
(rFVIII)
|
Advate
Adynovi
Afstyla
Elocta
Esperoct
Jivi
Kogenate Bayer
Kovaltry
Helixate NexGen
NovoEight
Nuwiq
Recombinate
ReFacto AF
Vihuma
Voncento
|
Treatment and prophylaxis of bleeding in patients with haemophilia A
(congenital factor VIII deficiency)
|
Plasma-derived FVIII concentrate
(pdFVIII)
|
Beriate
Haemoctin
Hemofil
Immunate
Monoclate
Octanate
Wilate
|
|
Recombinant FIX concentrate
(rFIX)
|
Alprolix
BeneFIX
Idelvion
NovoSeven
Reflixia
Rixubis
|
Treatment and prophylaxis of bleeding in patients with haemophilia B
(congenital factor IX deficiency)
|
Plasma-derived FIX concentrate
(pdFIX)
|
AlphaNine SD
Mononine
|
|
1 For plasma-derived products the list is a partial
list only, especially regarding nationally licensed products in EU. From
Jivi Report on the Maintenance of the Orphan Designation
(https://www.ema.europa.eu/en/documents/orphan-maintenance-report/jivi-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf).
|
1 For plasma-derived products the list is a partial
list only, especially regarding nationally licensed products in EU. From
Jivi Report on the Maintenance of the Orphan Designation
(https://www.ema.europa.eu/en/documents/orphan-maintenance-report/jivi-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf).
|
1 For plasma-derived products the list is a partial
list only, especially regarding nationally licensed products in EU. From
Jivi Report on the Maintenance of the Orphan Designation
(https://www.ema.europa.eu/en/documents/orphan-maintenance-report/jivi-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf).
|